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We report the case of glandular tularemia that developed in a man supposedly infected by a tick bite in Western Switzerland.
Francisella tularensis (F. tularensis) was identified. In Europe tularemia most commonly manifests itself as ulcero-glandular or
glandular disease; the diagnosis of tularemia may be delayed in glandular form where skin or mucous lesion is absent, particularly
in areas which are assumed to have a low incidence of the disease.
1. Clinical History
A 75-year-old man, living in a rural area of Western Switzer-
land, was admitted to the regional hospital in mid-July 2013
presenting with fever and myalgia lasting for 5 days. Family
members reported periods of confusion over the previous
24 hours. He never traveled abroad. He is retired from the
postal service and spent his free timewalking in the forest. He
had no direct contact with domestic or wild animals. Medical
history revealed diabetes type II and hypertension.
On admission the patient was febrile with moderate
agitation and confusion. There was no neck stiffness and the
neurological exam was unremarkable. Except for a painless
partially encrusted lesion on the left leg, the clinical examwas
assessed as normal. A brain computer tomography (CT) and
magnetic resonance imaging (MRI) excluded pathological
finding. Cerebral spinal fluid (CSF) analysis displayed 5.2𝐸 +
06/L mononuclear cells (reference value < 3.0𝐸 + 06/L) and
normal levels of protein and glucose. Blood test showed a
mild elevation of CRP at 23mg/L (reference value < 5mg/L).
The screening for the most common infectious causes of
encephalitis was performed including serological testing of
human immunodeficiency virus (HIV), immunoblot for Lyme
disease in serum and CSF, and molecular tests for Herpes
simplex virus (HSV), Varicella-zoster virus (VZV), Listeria
monocytogenes, and Bartonella henselae (B. henselae) in CSF.
All were negative. CSF and blood cultures were negative.
Patient was treated with ceftriaxone and acyclovir for
48 hours. He spontaneously recovered and was discharged
home after 5 days but was readmitted a few days later
with relapsing fever, confusion, and extreme fatigue. Clinical
exam was unchanged. Radiological workup including chest
and abdominal CT performed for investigation of fever of
unknown origin (FUO) revealed enlarged left femoral lymph
nodes. Because of the presumption of lymphoma, lymph
node biopsy was ordered. Histological examination revealed
a lymphadenitis with follicular hyperplasia including imma-
ture B lymphocytes on immunohistochemistry (IHC) and
sites of necrosis containing numerous granulocytes sur-
rounded by epithelioid cells (Figures 1(a) and 1(b)). There
was no sign for oncologic or infectious process. Bacteria,
including B. henselae andmycobacteria, were not detected by
Gram,Warthin-Starry, andZiehl-Neelsen stains. Serology for
Epstein-Barr virus (EBV) showed past infection. Serology for
B. henselae (IgG titer 1000, 𝑁 < 120; IgM titer < 100, 𝑁 <
100) was compatible with a current or an ancient infection.
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Figure 1: (a) HE, 4x: lymphadenitis with follicular hyperplasia and necrosis (arrow) surrounded by a histiocytic reaction. (b) HE, 20x:
necrotizing and granulomatous lymphadenitis, with numerous neutrophils cells (arrow).
However B. henselae specific PCR performed on paraffin-
embedded lymph node, as described below, was negative.
Serology for F. tularensis, performed by enzyme-linked
immunosorbent assay (ELISA) one month after the onset of
clinical manifestation, was compatible with a recent infection
(IgG 300U/mL,𝑁 < 10; IgM 122.4U/mL,𝑁 < 10). Definite
diagnostic of tularemia was confirmed by detection of F.
tularensis DNA (600 copies/mL) extracted from formalin-
fixed and paraffin-embedded tissue sections of the femoral
lymph nodes, as described below. Briefly, several tissue
sections were obtained from the pathologists and collected
in sterile tubes. After removal of paraffin using Xylol (65∘C)
and further rehydration via decreasing concentrations of
ethanol washes, DNA was extracted using MagNA Pure LC
automated system (Roche) with the MagNA Pure LC DNA
isolation kit I (Roche) and eluted in a final volume of 100 𝜇L.
Francisella specific PCR, targeting the fopA gene as previously
reported [1] and B. henselae specific PCR targeting the htr A
gene were performed.
The patient recovered after completion of 3 weeks of
ciprofloxacin treatment.
2. Discussion
Tularemia is a zoonosis mainly occurring in the Northern
Hemisphere. Humans may acquire the disease through the
handling of infected animals, ingestion of contaminated food
or water, inhalation of infective aerosols, and hematophagous
arthropod bites [2]. F. tularensis, the agent of tularemia, com-
prise 3 subspecies: F. tularensis subspecies (subsp.) holarctica,
tularensis, and mediasiatica. F. tularensis subsp. tularensis
and F. tularensis subsp. holarctica are clinically relevant for
humans. F tularensis subsp. tularensis is only present in
North America, while the subspecies holarctica is widespread
in the whole Northern Hemisphere [3]. Infection with F.
tularensis leads to 6 major clinical manifestations primarily
reflecting the route of infection and comprising ulceroglan-
dular, glandular, oculoglandular, oropharyngeal, pneumonic,
and typhoı¨dal syndrome. However, tularemia may present
with nonspecific symptoms and routine laboratory testing,
hampering its rapid diagnosis, especially in new endemic
region. Ordinarily the onset of disease is abrupt occurring
in an average of 3 days but ranging from 3 to 30 days after
exposure. Fever, chills, and headache malaise are frequent.
Persistent high fever is common. Ulceroglandular form is the
most common form in Europe, presenting commonly as a
localized lymphadenopathy. The initial skin lesion appears
as a cutaneous ulcer, usually solitary and evolving over the
course of the disease in “encrusted,” “ulcerous,” or “pustular”
wound [4].
The histologic examination of the regional lymph node
revealed a necrotizing and granulomatous lymphadenitis
[5]. Granulomatous lymphadenitis may be representative of
infectious or noninfectious processes. Noninfectious causes
encompass sarcoidosis or sarcoid-like reaction observed in
many underlying diseases. Infectious lymphadenitis is his-
tologically categorized into suppurative or nonsuppurative,
according to the presence or absence of granulocytes in
necrotic area. Follicular hyperplasia, B lymphocytosis, his-
tiocytic reaction, and granuloma with numerous granulo-
cytes in central necrosis are characteristically depicted in
adenitis associated with F. tularensis and B. henselae infection
[6]. In opposite, nonsuppurative adenitis, characterized by
granulocyte-free necrosis, is described in Mycobacterium
tuberculosis and Toxoplasma gondii infections. Thus, in
absence of available tissue for culture, histological descrip-
tion may presume the involved microorganism and suggest
additional tests to establish a definite diagnosis. Tularemia
is generally diagnosed either by serological tests compris-
ing microagglutination and enzyme-linked immunosorbent
assays (ELISA), by isolation of F. tularensis, or by performing
a specific F. tularensis PCR from clinical material including
wound drainage, lymph node aspirate, sputum, and blood.
The isolation of the agent of tularemia by culture or the
detection of F. tularensis DNA by PCR on fresh and frozen
tissues is particularly useful in the early phase of the disease
when antibodies are not yet present and the treatment ismore
effective [7].
In the present case the diagnosis was evoked lately in
spite of suggestive clinical and histological clues including
febrile lymphadenitis, encrusted cutaneous lesion attributed
to arthropod bite, and suppurative granulomatous adeni-
tis. While arthropod-borne diseases such as tick-borne
encephalitis and Lyme disease are well known by physicians,
Case Reports in Medicine 3
tularemia is still rarely evoked by doctors in Switzerland,
despite an increasing number of reported cases since 2008 [8–
11]. A study published in 2000 reported that out of 6071 Ixodes
ricinus ticks collected on Swiss Army training grounds in
five regions of Switzerland, 0.12% harbored F. tularensisDNA
[12].
Nervous system abnormalities are uncommon manifes-
tations of tularemia and have been exceptionally reported
as meningitis and encephalitis, probably following meninges
seeding during untreated bacteremia [13–16]. Meningitis or
encephalitis may occur following all of the 6 syndromes
caused byF. tularensis, developing in amedian of 5 days, rang-
ing from 3 to 30 days after the onset of initial manifestation
[17]. CSF analysis usually reveals mononuclear pleocytosis,
variable level of protein and glucose, and generally negative
Gram stain [17, 18]. Based on unremarkable CSF analysis and
CNS radiologic evaluation, the cause of the confusion and
the contribution of F. tularensis in the abnormal behavior
observed in our patient could not be established.
Aminoglycosides (streptomycin and gentamicin), fluoro-
quinolone, and tetracyclines are the drugs commonly used
to treat tularemia. Until recently macrolides were consid-
ered effective in cases acquired in Switzerland and Western
European countries. Azithromycin was even considered as
first line treatment option during pregnancy in France [19].
With the growing interest in F. tularensis biology and the
advent of novel molecular technologies, the genome of an
increasing number of strains is sequenced leading to the
discovery of new subgroups [20–22]. In Europe, strains of
F. tularensis subsp. holarctica belonging to groups B.13 and
B.FTNF002-00 are predominant [23]. Until recently, only
strains of group B.FTNF002-00 were isolated from human
and animal tularemia cases in Switzerland. However, Origgi
and colleagues reported that strains belonging to group B.13
are circulating in Switzerland in the same areas than strains
of group B.FTNF002-00 at least since 2012 [24]. Because of
the antibiotic resistance profile of this group, this discovery is
relevant for clinical practice. Indeed, while the strains belong-
ing to groupB.FTNF002-00 are sensitive to erythromycin, the
strains of groupB.13 are not.Macrolides should not be recom-
mended to treat cases acquired in Switzerland without prior
typing of the strains. The minimal inhibitory concentration
(MIC) values of antibiotic drugs relevant to clinical use (con-
centrations tested: gentamycin [0.12–16mg/L], tetracycline
[0.25–16 𝜇g/mL], erythromycin [0.5–32 𝜇g/mL], chloram-
phenicol [2–32 𝜇g/mL], and ciprofloxacin [0.06–4 𝜇g/mL]),
were performed on a panel of 24 strains isolated between
1996 and 2013 from human and animal cases of tularemia in
Switzerland. Ciprofloxacinwas found to show the lowestMIC
values and prevented growth of all strains at 0.06𝜇g/mL [24].
These results are in accordance with previous studies [25–27].
Gentamicin used to be the reference treatment for tularemia.
Because of its IV formulation and side effects, its use is cur-
rently restricted to severe tularemia cases. Fluoroquinolone
and tetracyclines, especially ciprofloxacin and doxycycline,
respectively, are advocated as first line drugs for patients
with diseases of mild to moderate severity. Treatment failures
and relapses may occur in up to 10% of patients treated
with a fluoroquinolone and even more frequently when a
tetracycline is administered; however the natural acquisition
of antibiotic resistance has not been proven so far.
Tularemia should be considered in presence of fever and
enlarged lymphnode in countrieswhere tularemia is endemic
or sporadic cases in animals and humans occur. Localization
of adenitis often reflects the route of infection. Primary
respiratory tract infections generally involve mediastinal
and/or hilar lymph nodes and skin inoculation implicate
regional lymph nodes, while oropharyngeal and conjunctival
contamination induce adenopathy in cervical, preauricular,
and submandibular regions. Meticulous examination of skin
and mucosa to identify the portal of entry and inquiry on
recent tick bite may guide the diagnosis. Oropharyngeal
tularemia should be excluded before making the diagnosis of
tuberculosis in presence of cervical lymphadenitis, especially
if histology displays suppurative necrotizing granuloma-
tous lymphadenitis, and tularemia should be considered in
patients with a history of fever and ulcerative skin lesion
following arthropod bite.
In the presence of enlarged lymphnode and lung infiltrate
careful interrogation on exposition to contaminated dust or
sick animals may orientate the diagnosis toward tularemia or
Q fever.
Due to its convenient use, its rare side effects, and its
lowest MIC compared to that of other effective antibiotics,
quinolone may be considered as the first line treatment in
nonsevere tularemia.
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